Concepedia

Margherita Carucci

MC

Statistics

Publications

5

Citations

454

H-Index

5

Active since

2018

Affiliations

Cardiff University(Current)

Ipswich Hospital

Velindre Cancer Centre

University of Manchester

University of Leeds

Margherita Carucci is an author at Cardiff University specializing in oncology, medicine, and pharmacology.

Publications per year

2018–2022

5

Publications

5

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert H. Jones, Margherita Carucci, Angela Casbard et al. · Journal of Clinical Oncology · 2019 · 38 citations

Medicine, Oncology, Pharmacology +16

Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase <scp>II</scp> trial (<scp>RT</scp>3<scp>VIN</scp>)

S E F Jones, T. Madden, Alison Fiander et al. · BJOG An International Journal of Obstetrics & Gynaecology · 2018 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · Journal of Clinical Oncology · 2022 · 11 citations

Medicine, Oncology, Pharmacology +17

1–5 of 5